Although cervical cancer screening has been successful in the United States, little is known about the optimal circumstances under which screening can safely end. This study will address this research gap by estimating cervical cancer screening benefits a...
Funder: National Cancer Institute
Investigator: Silverberg, Michael
|
Cardiovascular disease (CVD) is a large and growing public health problem, especially for people with HIV (PWH). Within Kaiser Permanente, we use a syndemic approach to investigate combinations of social and biological conditions that may act synergistica...
Funder: National Heart, Lung, and Blood Institute
Investigator: Silverberg, Michael
|
The purpose of this study is to initiate a 5-year collaboration between the Centers for Disease Control and Prevention (CDC) and 3 KP regions (KPNC, KPSC and KPMAS) to include PrEP prescription data and key demographics in the U.S. Department of Health an...
Funder: Centers for Disease Control and Prevention
Investigator: Silverberg, Michael
|
This study will assess the safety and tolerability of rMenB+OMV NZ and MenACWY vaccines when administered concomitantly or alone in healthy subjects 16-18 years of age.
Funder: GlaxoSmithKline PLC
Investigator: Klein, Nicola
|
We are providing technical expertise, consultation, and enrolling participants in a randomized clinical trial to evaluate the safety of simultaneous mRNA COVID-19 vaccine with other childhood vaccines in young children aged 6 months to 5 years.
Funder: Centers for Disease Control and Prevention
Investigator: Klein, Nicola
|
We conduct administrative tasks, data management, and contribute to vaccine safety assessments to support the management and development of the ongoing work of the VSD. This includes
producing and maintaining a high-quality electronic data infrastructure ...
Funder: Centers for Disease Control and Prevention
Investigator: Klein, Nicola
|
This observational cohort study will determine the effectiveness of the Adacel vaccine against pertussis disease in infants aged 2 months and 1 year when administered at any time during pregnancy.
Funder: Sanofi Pasteur S.A.
Investigator: Klein, Nicola
|
This study aims to identify and characterize persons who are at risk of developing or who have developed post-COVID conditions, including those with medically unexplained illness in certain risk groups, and identify risk factors for post-COVID conditions.
Funder: Centers for Disease Control and Prevention
Investigator: Skarbinski, Jacek
|
The overall goals are to: Determine COVID-19 vaccine effectiveness in pregnant women for preventing laboratory-confirmed COVID-19 and hospitalization for COVID-19 using real-world clinical data; Determine effectiveness of maternal COVID-19 vaccination dur...
Funder: National Institute of Allergy and Infectious Diseases
Investigator: Zerbo, Ousseny
|
The Study of Transition, Outcomes and Gender (STRONG) is an ongoing cohort study of transgender people enrolled in Kaiser Permanente (KP) integrated health care plans in Georgia (KPGA), Northern California (KPNC) and Southern California (KPSC), and includ...
Funder: National Institute on Aging
Investigator: Silverberg, Michael
|
We are studying the genomes of SARS-CoV-2 in persons with COVID-19 with and without vaccination to identify and describe variants circulating within our patients, including variants of concern (such as Delta or Omicron. We also are assessing which shared ...
Funder: The Rockefeller Foundation
Investigator: Skarbinski, Jacek
|
The goals of this study are to identify primary care settings that serve non-U.S.born persons at risk for latent tuberculosis infection and tuberculosis disease; collect retrospective and prospective electronic medical record data; design and implement cl...
Funder: Centers for Disease Control and Prevention
Investigator: Skarbinski, Jacek
|
The goal of this K01 Career Development Award is to receive mentored training on the development of risk prediction models for dementia in people with HIV using electronic health records data.
The project will quantify the contribution of HIV- and non-HIV...
Funder: National Institute of Allergy and Infectious Diseases
Investigator: Lam, Jennifer
|
This study will identify primary care systems and settings that serve non-U.S.-born persons at risk for latent tuberculosis infection (LTBI) and tuberculosis disease; collect retrospective and prospective electronic medical record data; design and impleme...
Funder: Centers for Disease Control and Prevention
Investigator: Skarbinski, Jacek
|
In partnership with the California Emerging Infection Program and the California Department of Public Health, Kaiser Permanente Northern California will contribute to statewide whole genome sequencing efforts for surveillance for SARS-CoV-2 variants of co...
Funder: Centers for Disease Control and Prevention
Investigator: Skarbinski, Jacek
|
The goal of this study is to use electronic medical records from 2016 to 2020 to evaluate the protective effect of MenB-4C vaccine against gonococcal infections among 16- to 23-year-old persons.
Funder: Centers for Disease Control and Prevention
Investigator: Zerbo, Ousseny
|
This study will evaluate the safety, tolerability, and efficacy of a booster dose of BNT162b2 when administered to study participants who previously received 2 doses of BNT162b2 at least 6 months prior to randomization.
Funder: Pfizer Inc.
Investigator: Klein, Nicola
|
This phase I open-label dose-finding study will evaluate the safety, tolerability, and immunogenicity of a Sars-Cov-2 RNA vaccine candidate against COVID-19 in healthy 12-year-old children.
Funder: Pfizer Inc.
Investigator: Klein, Nicola
|
This study will evaluate extended 2-dose regimens in boys and girls ages 10 to 15 who previously received 1 dose of 9vHPV vaccine and did not complete the series and in HPV vaccine-naive boys and girls ages 9 to 14. Both groups will be compared with young...
Funder: Merck ＆ Company, Inc.
Investigator: Klein, Nicola
|
This prospective, observational cohort study, an extension of clinical trial V503-069, will enroll and administer a second dose of 9vHPV to approximately 200 children/teens ages 10 to 15 who received their first 9vHPV vaccine at least 1 year prior. These ...
Funder: Merck ＆ Company, Inc.
Investigator: Klein, Nicola
|
Cancer is the leading cause of death among persons with HIV (PWH). Studies have found significant disparities in cancer therapy initiation and survival for PWH compared with the general population. This study will evaluate differences in cancer treatment ...
Funder: National Cancer Institute
Investigator: Silverberg, Michael
|
This study will evaluate extended 2-dose regimens in 2 different populations: (1) boys and girls 10 to 15 years of age who previously received 1 dose of 9vHPV vaccine and did not complete the series and (2) HPV vaccine-naive boys and girls 9 to 14 years o...
Funder: Merck ＆ Company, Inc.
Investigator: Klein, Nicola
|
To demonstrate that the immune responses induced by BNT162b2 are consistent across the 3 U.S. lots (Lots 1, 2, and 3) in participants without evidence of SARS-CoV-2 infection during the study.
Funder: Pfizer Inc.
Investigator: Klein, Nicola
|
This work will support and contribute to the COVID-19 vaccine safety work of the VSD: managing site contributions, and participating on working groups and attending conference calls; providing high-quality electronic data for COVID-19 vaccine safety acti...
Funder: Centers for Disease Control and Prevention
Investigator: Klein, Nicola
|
Study will perform sequencing on 300 specimens from a mixture of Flublok Quadrivalent vaccine recipients, SD-IIV4 recipients, and unvaccinated individuals; and describe the molecular epidemiology of approximately 300 influenza strains causing disease in v...
Funder: Sanofi Pasteur S.A.
Investigator: Klein, Nicola
|
|
